Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Hemostemix V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc is a clinical-stage biotechnology company. The company's principal business activity is to develop, manufacture, and commercialize blood-derived cell therapies for medical conditions. Its technology platform for developing autologous cell therapies is for the treatment of vascular diseases. The group's clinical-stage candidate, ACP-01, is an autologous cell therapy for the treatment of critical limb ischemia.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 
@ the Bell: Markets retreat at the end of the week
Canada’s main stock index posted a triple digit decline by Friday’s close thanks to losses in the technology and base metal sectors. The telecom and utilities sectors were the only ones to see an... read article.


My guess is that this will move ahead faster then we all think ,Inorder for back to back funding looks like they need the money faster then we imagined but at the same time if things pan out i can more

Rockwell Medical Announces Second Quarter 2022 Results

Revenue was $18.7 million for the second quarter 2022, a 16% increase over the first quarter 2022, representing the highest quarterly revenue to-date for Rockwell more


I wouldn't worry about warrants or that kind of dilution until we have any reason to believe we are going to hit 55 cents. Without positive results that isn't going to happen. If they more


Ya I'm getting concerned about my investment here now with this new pp. shite the dilution now will be over 200 million shares with all the warrants outstanding and the shares available to more


Either they're sitting on junk results or there is some impedement to getting it done that requires more time and money to overcome. It says in the original PP prospectus that 2.5M$ will be more


WTF... is this in addition to the previously announced one that wasn't filled??????  rate and reply

New Press Release - Hemostemix Announces Unit Private Placement

Calgary, Alberta--(Newsfile Corp. - August 19, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce a non-brokered private placement of up to five Million Units priced at $0.30 each, closing in tranches. Each Unit consists of article.
The Market Herald's Weekly Cannabis Report
Tilray Brands, Inc. | LinkedInTilray Brands’ (TLRY) medical cannabis division, Tilray Medical,has received approval to commercialize its medical cannabis products in Poland.The approval allows... read article.

Thematica Insights Report & Investor Guide

Thematica Report: Exploring the opportunities in battery metals

The Market Herald launches Thematica’s latest report: Battery Metals. Understand how battery metals are driving the future. Download today!
Buzz on the Bullboards: Debates among the top sectors
If you’re looking to see the stocks that investors have been keeping an eye on over the past week, you’ve come to the right place. The Bullboard community regularly acts as a microcosm of investor... read article.


This second closing for $ is really ticking me off. This tells me they are nowhere near having the data analyzed, so I'd say prob 6 plus months to get some formalized results OR they got more

RE:RE:RE:RE:RE:RE:ACP-01 Midpoint Analysis

Also if I were Aspire and knew I had put out misleading info for which i could be held liable I would definitely hold on to the evidence and have any settlement include a clause stating i can't more

RE:RE:RE:RE:RE:ACP-01 Midpoint Analysis

Ya that would be fraud you would think and it has always made me second guess how this data will pan out. Then again, you wouldn't be able to charge them with fraud without having the data more

RE:RE:RE:RE:ACP-01 Midpoint Analysis

Thanks for informative response. If Accudata and Aspire misrepresented the data, that would be fraud - no? But I see the court accepted Aspire's 'Motion to Dismiss' Count VII (fraud) in more

Moving Forward

Nice to see we are in full motion,I beleive we are in for a big ride anytime coming soon.GLA.--{Results are not that far off and we can be off to the races}  rate and reply

Proceeds to commence buildout of production ACP-01

Proceeds from the Offering are expected to be used to pay finder fees payable in connection with the closing, current filing and regulatory fees, debt reduction and commencing the more


They are still needing new cash!!! Man this is going to be a while yet until they release the results!   rate and reply

New Press Release - Hemostemix Announces Closing of Second Tranche of UNIT Private Placement

Calgary, Alberta--(Newsfile Corp. - August 12, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") announces that it has closed a second tranche of its previously announced non-brokered private placement of units ("Units") as announced on May 19, 2022 for article.

RE:RE:RE:ACP-01 Midpoint Analysis

Undisclosed amount in a cash settlement for all rights and data. The assumption is that Aspire released that report on the midpoint in an attempt to disuade management from going after the more

RE:RE:ACP-01 Midpoint Analysis

What were the terms of the court settlement between HEM and Aspire?  rate and reply

RE:ACP-01 Midpoint Analysis

Try again troll. The article was from 2020. If the results were not great, why would Aspire fight tooth and nail not to return the results? By all means, if you can lower the SP so I can buy more

ACP-01 Midpoint Analysis

Midpoint analyses didn't look too encouraging... more

Congratulate Gusthegreek for winning the board idiot award

Gus is desperate and you find him crying on sub-penny Marijuana boards trying to pay his loans. We are setting a GO Fund Me page for him soon  rate and reply

Short Positions

Shorts are down to less than 2000 shares!!!  rate and reply